Quantity of eligible patients: CDEC talked over the uncertainty in the volume of clients with moderately serious to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical professionals consulted by CADTH indicated that some patients who will be categorized as getting moderate or reasonable illness may have a critical https://johnathangkpsu.blogs-service.com/66934512/hemgenix-fundamentals-explained